Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | GOT1 | P17174 | 6/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2961026 | 0.81 | CHRM4 (0.62) | MAPTHTR6CHRM4HSD11B1GBA1 | |
| SCHEMBL2961244 | 0.81 | TRPV1 (0.53) | MAPTDRD2HTR6CHRM4HSD11B1 | |
| SCHEMBL6863838 | 0.79 | ADRB1 (0.60) | GAAMAPTDRD2DRD4DRD3 | |
| SCHEMBL3223609 | 0.79 | CHRM4 (0.57) | MAPTDRD2DRD4DRD3HTR6 | |
| SCHEMBL5331434 | 0.76 | CHRM4 (0.64) | GAAMAPTCHRM4HSD11B1GBA1 | |
| SCHEMBL2963243 | 0.75 | CHRM4 (0.56) | MAPTHTR6CHRM4HSD11B1GBA1 | |
| SCHEMBL2961967 | 0.75 | ALDH1A1 (0.61) | GAAMAPTCHRM4HSD11B1GBA1 | |
| SCHEMBL3216764 | 0.75 | ALDH1A1 (0.64) | MAPTCHRM4HSD11B1LMNA | |
| SCHEMBL10723724 | 0.75 | CHRM4 (0.64) | MAPTCHRM4GBA1LMNA | |
| SCHEMBL3223553 | 0.74 | CHRM4 (0.61) | MAPTHTR6CHRM4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | claimed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | claimed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| EP-1866298-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105127-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223829-A1 | Hydroxysteroid dehydrogenase inhibitors | HSD17B1, HSD17B3, HSD17B2 | GAA 455/4885MAPT 3168/4885DRD2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.